Danielle Brander, MD

Drs. Flinn and Brander reflect on the key long-term findings from the SEQUOIA trial, with particular emphasis on durability of response and outcomes in high-risk patient populations.

In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era.